These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19839932)

  • 1. The role of pemetrexed combined with targeted agents for non-small cell lung cancer.
    Konopa K; Jassem J
    Curr Drug Targets; 2010 Jan; 11(1):2-11. PubMed ID: 19839932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
    Li T; Lara PN; Mack PC; Perez-Soler R; Gandara DR
    Curr Drug Targets; 2010 Jan; 11(1):85-94. PubMed ID: 19839922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of pemetrexed and platinums combination in patients with non-small cell lung cancer.
    Chen M; Shao W; He J; Wang D
    Curr Drug Targets; 2010 Jan; 11(1):29-36. PubMed ID: 19839930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC).
    Wagner TD; Yang GY
    Curr Drug Targets; 2010 Jan; 11(1):67-73. PubMed ID: 19839925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed disodium for the treatment of NSCLC: an update.
    Hsu JY; Wakelee H
    Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
    Giovannetti E; Honeywell R; Hanauske AR; Tekle C; Kuenen B; Sigmond J; Giaccone G; Peters GJ
    Curr Drug Targets; 2010 Jan; 11(1):12-28. PubMed ID: 19839931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seeking new options for the treatment of small-cell lung cancer.
    Socinski MA
    Lung Cancer; 2005 Oct; 50 Suppl 1():S25-6. PubMed ID: 16291430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of second-line non-small-cell lung cancer.
    Hanna N
    Lung Cancer; 2005 Oct; 50 Suppl 1():S15-7. PubMed ID: 16291425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
    Joerger M; Omlin A; Cerny T; Früh M
    Curr Drug Targets; 2010 Jan; 11(1):37-47. PubMed ID: 19839929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
    Ngeow J; Toh CK
    Curr Drug Targets; 2010 Jan; 11(1):61-6. PubMed ID: 19839926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
    Scagliotti GV
    Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer.
    Tucker S
    Curr Drug Targets; 2010 Jan; 11(1):58-60. PubMed ID: 19839927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
    Lee DH; Lee JS; Kim SW; Rodrigues-Pereira J; Han B; Song XQ; Wang J; Kim HK; Sahoo TP; Digumarti R; Wang X; Altug S; Orlando M
    Eur J Cancer; 2013 Oct; 49(15):3111-21. PubMed ID: 23890768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
    Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.